**TABLE OF CONTENTS**

HEADER ................................................................................................................. 1  
ABSTRACT ............................................................................................................... 1  
PLAIN LANGUAGE SUMMARY .............................................................................. 2  
BACKGROUND ...................................................................................................... 2  
OBJECTIVES ......................................................................................................... 4  
METHODS ............................................................................................................. 4  
RESULTS ............................................................................................................... 6  
  Figure 1. ................................................................................................................... 8  
  Figure 2. ................................................................................................................... 10  
  Figure 3. ................................................................................................................... 12  
DISCUSSION .......................................................................................................... 14  
AUTHORS’ CONCLUSIONS ................................................................................... 14  
ACKNOWLEDGEMENTS ......................................................................................... 15  
REFERENCES ........................................................................................................ 15  
CHARACTERISTICS OF STUDIES ....................................................................... 17  
DATA AND ANALYSES ......................................................................................... 26  
  Analysis 1.1. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 1 Treatment failure. 28  
  Analysis 1.2. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 2 Admission to hospital. 29  
  Analysis 1.3. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 3 PEF @ 30 minutes (% predicted). . 30  
  Analysis 1.4. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 4 PEF @ 120 minutes (% predicted). . 30  
  Analysis 1.5. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 5 FEV1 @ 30 minutes (litres/sec). . . 31  
  Analysis 1.6. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 6 FEV1 @ 30 minutes (% predicted). . 31  
  Analysis 1.7. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 7 FEV1 @120 mins (litres/sec). . 32  
  Analysis 1.8. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 8 Pulmonary index @ 30 mins. . . 32  
  Analysis 1.9. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 9 Pulmonary index @ 120 mins. . . 33  
  Analysis 2.1. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 1 Treatment failure. 33  
  Analysis 2.2. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 2 Admission to hospital. 34  
  Analysis 2.3. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 3 Participants requiring no repeat nebulisation. 35  
  Analysis 2.4. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 4 PEF @ 30 minutes (% predicted). . 35  
  Analysis 2.5. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 5 PEF @ 120 minutes (% predicted). . 35  
  Analysis 2.6. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 6 FEV1 @ 30 minutes (litres/sec). . . 36  
  Analysis 2.7. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 7 FEV1 @120 mins (litres/sec). . 36  
  Analysis 2.8. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 8 Pulmonary index @ 30 mins. . . 37  
  Analysis 2.9. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 9 Pulmonary index @ 120 mins. . . 38  
ADDITIONAL TABLES .......................................................................................... 38  

**Anticholinergic therapy for acute asthma in children (Review)**

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Anticholinergic therapy for acute asthma in children

Laurel Teoh1,2, Christopher J Cates3, Mark Hurwitz4, Jason P Acworth5, Peter van Asperen6,7, Anne B Chang2,8,9

1Department of Paediatrics and Child Health, The Canberra Hospital, Canberra, Australia. 2Menzies School of Health Research, Charles Darwin University, Casuarina, Australia. 3Population Health Sciences and Education, St George's, University of London, London, UK. 4Department of Thoracic Medicine, The Canberra Hospital, Canberra, Australia. 5Emergency Medicine, Royal Children's Hospital, Brisbane, Australia. 6Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, Australia. 7Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney Children's Hospitals Network, Sydney, Australia. 8Queensland Children's Respiratory Centre, Royal Children's Hospital, Brisbane, Australia. 9Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, Australia

Contact address: Laurel Teoh, laurel.teoh@act.gov.au, laurelteoh@yahoo.com.au.

Editorial group: Cochrane Airways Group.
Review content assessed as up-to-date: 30 April 2011.


Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Inhaled anticholinergics as single agent bronchodilators (or in combination with beta2-agonists) are one of the several medications available for the treatment of acute asthma in children.

Objectives

To determine the effectiveness of only inhaled anticholinergic drugs (i.e. administered alone), compared to a control in children over the age of two years with acute asthma.

Search methods

The Cochrane Register of Controlled Trials (CENTRAL), and the Cochrane Airways Group Register of trials were searched by the Cochrane Airways Group. The latest search was performed in April 2011.

Selection criteria

We included only randomised controlled trials (RCTs) in which inhaled anticholinergics were given as single therapy and compared with placebo or any other drug or drug combinations for children over the age of two years with acute asthma.

Data collection and analysis

Two authors independently selected trials, extracted data and assessed trial quality.

Main results

Six studies met the inclusion criteria but were limited by small sample sizes, various treatment regimes used and outcomes assessed. The studies were overall of unclear quality. Data could only be pooled for the outcomes of treatment failure and hospitalisation. Other data could not be combined due to divergent outcome measurements. Meta-analysis revealed that children who received anticholinergics alone were significantly more likely to have treatment failure compared to those who received beta2-agonists from four trials on 171 children (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75). Also, treatment failure on anticholinergics alone was more likely than when...
Anticholinergic therapy for acute asthma in children

Asthma is a condition that affects the airways (tubes carrying air in and out of the lungs). During an asthma exacerbation (attack), the airways narrow and drugs can be taken to dilate, or widen, the airways. Common bronchodilators (medicines used to widen the airways) are short-acting beta₂-agonists (e.g. salbutamol) or anticholinergics (e.g. ipratropium bromide). In this review, we examined if the use of anticholinergic inhalers during an asthma attack in children aged over two years is effective compared to either placebo or another bronchodilator. We also looked at combinations of anticholinergic plus a beta₂-agonist compared to an anticholinergic on its own.

We found six small trials of unclear quality answering these two questions. We found data from four trials on 171 children comparing anticholinergics with beta₂-agonists. Children on anticholinergics alone were significantly more likely to experience treatment failure than those on beta₂-agonists (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75). We also found data from four trials on 173 children comparing children on anticholinergics alone with children on anticholinergics plus beta₂-agonists. In this case, treatment failure was more likely in children taking anticholinergics only than if they were combined with beta₂-agonists (OR 2.65; 95% CI 1.2 to 5.88).

In summary, we found that inhaled anticholinergics used on their own are less effective than inhaled beta₂-agonists used alone or in combination with anticholinergics. Inhaled anticholinergics seem safe, with no significant side effects apparent.

Background

Inhaled anticholinergics as single agent bronchodilators (or in combination with beta₂-agonists) are one of the several medications available for the treatment of acute asthma in children. Ipratropium bromide, an inhaled anticholinergic agent, has been used extensively in emergency departments as adjunctive therapy with beta₂-agonists for the emergency treatment of acute asthma exacerbations. The objective of this review was to determine the effectiveness of only inhaled anticholinergic drugs (i.e. administered alone), compared to a control or combination treatment in children over the age of two years with acute asthma.

Description of the condition

Asthma is an inflammatory disorder of the airways in which many cells and cellular elements play a role. In susceptible individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness and cough. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment. The inflammation also causes an associated increase in the existing bronchial hyperresponsiveness to a variety of stimuli (NHLBI 2007). Airflow obstruction (excessive airway narrowing) in asthma is the result of contraction of the airway smooth muscle and swelling of the airway wall due to smooth muscle hypertrophy and hyperplasia, inflammatory cell infiltration, oedema, goblet cell and mucous gland hyperplasia, mucous hypersecretion, protein deposition including collagen and epithelial desquamation. Potential triggers for the inflammatory process in asthma include allergy, viral res-
piratory infections, irritants such as tobacco smoke, air pollutants and occupational dusts, gases and chemicals, certain drugs, and non-specific stimuli such as cold air exposure and exercise (NAC 2006).

**Description of the intervention**

Inhaled anticholinergics are bronchodilators. Ipratropium bromide is the most studied anticholinergic bronchodilator, and now most widely used of anticholinergic agents. Ipratropium bromide has been used extensively in emergency departments as adjunctive therapy with beta-agonists for the emergency treatment of acute asthma exacerbations. Multiple doses of anticholinergics in combination with beta-2-adrenergic agents have shown to be beneficial in adults (Undem 2001) and of some merit in school-aged children with severe asthma exacerbation (Plotnick 2008). Current guidelines recommend the use of a combination of inhaled beta-2-agonists and anticholinergics, particularly for patients with acute severe or life-threatening asthma in the emergency setting. Anticholinergics tend not to be used as first-line drugs for asthma exacerbation (Gross 1988).

Ipratropium anticholinergics are the drugs of choice in bronchospasm provoked by psychogenic stimuli and beta-2-blockers (Gross 1988; Beakes 1997). Ipratropium bromide also appears to have some benefit in nocturnal asthma (Beakes 1997). However, the principal clinical use of ipratropium bromide is in the treatment of adult patients with chronic obstructive pulmonary disease (Brown 2001).

**How the intervention might work**

Airway calibre is controlled in health and disease by many influences. The parasympathetic nervous system is one among the many mechanisms, which regulates the airway calibre by varying the bronchomotor tone. Muscarinic receptors are widely distributed in the airways and the release of acetylcholine at these sites results in both smooth muscle contraction and release of secretions from submucosal glands. An opportunity for therapeutic intervention exists at the level of these muscarinic receptors. Anticholinergic agents such as atropine and its analogues are competitive inhibitors of acetylcholine and may result in bronchodilatation by reducing the tone of smooth muscles (Gross 1988). Anticholinergic agents act at muscarinic receptors, competitively inhibiting the effects of acetylcholine. Acetylcholine acts by causing smooth muscle constriction, which provides bronchomotor tone. By antagonising the effects of acetylcholine, cholinergic bronchomotor tone is inhibited and the vagal reflexes that mediate bronchoconstriction are blocked (McDonald 2010). Cholinergic-induced bronchoconstriction appears to involve primarily the large airways, whereas beta-2-agonist medications relax both large and small airway constriction equally (Rodrigo 2002).

Ipratropium bromide (8-isopropyl-noratropine-methobromide) is a synthetic quaternary ammonium congener of atropine. Ipratropium bromide differs from atropine and other naturally occurring anticholinergic alkaloids in one major aspect - it is insoluble in lipids (although freely soluble in water) and crosses biological barriers with difficulty. One could thus describe ipratropium bromide as a topical form of atropine and hence virtually free of systemic side effects. Neither atropine nor ipratropium bromide is selective for the subtypes of muscarinic receptors. It was the first anticholinergic agent to be approved for use as a bronchodilator in adults and children (for acute asthma in children), with a wide therapeutic margin of safety and has no important side effects (Gross 1988; Brown 2001). Ipratropium bromide is a less potent bronchodilator than beta-2-adrenergic agents. The onset of action of ipratropium is slower than short-acting beta-2-adrenergic agents (30 to 90 minutes versus 5 to 15 minutes).

**Why it is important to do this review**

The role of anticholinergic drugs for wheezing in children under the age of two years has been reviewed (Everard 2005). The authors concluded that there is not enough support for the uncritical use of anticholinergic therapy for wheezing under the age of two years. The review by Plotnick et al focused specifically on combined treatment with anticholinergics and beta-2-agonists in asthmatic children over the age of two years and concluded that anticholinergics plus beta-2-agonists have a beneficial effect over beta-2-agonists alone in improving lung function significantly and the addition of multiple doses of anticholinergics to beta-2-agonists reduced the risk of hospital admissions in children with predominantly severe exacerbations (Plotnick 2008). Plotnick et al also found that there was no conclusive evidence for using multiple doses of anticholinergics in children with mild or moderate asthma exacerbations. There is good evidence for the safety and efficacy of frequent doses of ipratropium bromide (every 20 to 30 minutes) used in addition to beta-2-agonists for the first two hours of a severe asthma attack in children over two years (BTS 2009). The addition of ipratropium bromide to beta-2-agonists for severe acute asthma may lead to some improvement in clinical symptoms and reduce the need for more intensive treatment in children less than two years. It does not significantly reduce the length of hospital stay either in combination with beta-2-agonists or in comparison with placebo (Everard 2005; BTS 2009). When investigating the therapeutic effect of an agent that may be used in combination with another agent, it is important to establish separately the effectiveness of both the agents over placebo. It is also essential to compare the beneficial effect of the combined agents over placebo as well as the individual agents. In this way it is possible to establish: a) if the single agents have a therapeutic effect; and b) if there is an additive or synergistic effect from combining the agents.
This review focuses on the effectiveness of anticholinergic drugs (without beta2-agonists) in children aged over two years with acute asthma. By comparing the effect of anticholinergics as single agents with that of other single agents and with combined therapy (anticholinergics with beta2-agonists) as reviewed previously (Plotnick 2008), we aim to establish the role of anticholinergics as a monotherapy in the treatment of children over two years of age with acute asthma.

OBJECTIVES

To determine the effectiveness of inhaled anticholinergic drugs (used alone) compared to a control or combination treatment in children over the age of two years with acute asthma.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs) in which only inhaled anticholinergics were given compared with placebo, or any other drug, or drug combinations for children over the age of two years with acute asthma.

Types of participants

We included trials of children aged two to eighteen years with acute asthma in all settings (emergency room, observation unit, in-patient, out-patient, general practice and home). Asthma must have been physician diagnosed or must have satisfied the criteria established internationally (such as BTS 2009 guidelines). We excluded studies involving children under the age of two years since difficulties arise in establishing the diagnosis of asthma unequivocally. Also they have been reviewed previously (Everard 2005).

Types of interventions

Inhaled anticholinergic drugs delivered by any means; nebulised or by metered dose inhalers with or without spacer devices, and with or without facemask. We included all doses and dosing regimens. We included the following comparisons.

1. Anticholinergics versus placebo.
3. Anticholinergics versus anticholinergics plus beta2-agonists.
4. Anticholinergics versus any other drugs or drug combinations.

Types of outcome measures

Outcome measures in the studies are summarised in Table 1.

Primary outcomes

1. Treatment failure
2. Admission to hospital

Secondary outcomes

1. Changes in symptoms or symptom scores
2. Requirement for additional medication
3. Changes in pulmonary function tests (peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1))
4. Effects on oxygenation
5. Duration of hospital stay
6. Adverse effects
7. Withdrawals

Search methods for identification of studies

The methods used to identify the studies are summarised below.

Electronic searches

We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see Appendix 1 for further details). We searched all records in the CAGR coded as ‘asthma’ using the following terms: (“cholinergic antagonists” or “anticholinergic” or “anti-cholinergic” or “cholinergic” or “muscarinic” or “antimuscarinic” or “ipratropium” or “tiotropium” or “atropine” or “atrovent” or “oxitropium” or “Sch1000” or “duovent”, all as (textword) or (MeSH )) AND (“asthma “or “wheez” or “respiratory sounds” or “bronchial spasm”, “bronchospas” or “bronch” or “spasm” or “bronchoconstrict” or “bronchoconstriction” or “bronch” or “con-strict”, all as (textword) or (MeSH )) AND (“adolescent” or “child” or “paediat” or “pediat” or “infan” or “toddler” or “bab” or “young” or “preschool” or “pre school” or “pre-school” or “new-born” or “new born” or “new-born” or “neonat” or “neonat”, all as (textword) or (MeSH )). We also conducted an additional search of CENTRAL (see Appendix 2). We searched all databases from their inception to...
April 2011 and we imposed no restriction on the language of publication.

Searching other resources
We checked reference lists of all primary studies and review articles for additional references.

Data collection and analysis
From the title, abstract, or descriptors, two review authors (LT and AC) independently reviewed literature searches to identify potentially relevant trials for full review. We conducted searches of bibliographies and texts to identify additional studies.

Selection of studies
From the full text, using specific criteria, two reviewers (LT and AC) independently selected trials for inclusion. We resolved disagreement by consensus.

Data extraction and management
LT and AC extracted data for the trials for the outcomes above. We combined all trials using Review Manager 5 (RevMan 2011).

Assessment of risk of bias in included studies
Two review authors (LT and AC) performed methodological quality assessment, using the 'risk of bias' tool described in the Cochrane Handbook of Systematic Reviews of Interventions (Higgins 2011), focusing on:
- random sequence generation;
- allocation concealment; and
- blinding
We graded each domain as either 'high', 'low' or 'unclear' risk of bias.

Measures of treatment effect
We obtained all outcomes directly from the publications of the included studies.

Continuous Outcomes
For continuous outcomes measured on the same metrics, we calculated individual and pooled statistics as weighted mean differences (WMDs) with 95% confidence intervals (CIs). For continuous outcomes measured on different metrics, we combined data with a standardised mean difference (SMD).

Dichotomous Outcomes
For dichotomous variables, we calculated individual and pooled statistics as odds ratios (ORs) with 95% CIs.

Unit of analysis issues
None relevant.

Dealing with missing data
The review authors did not contact any study authors as it was not felt necessary and the studies were also not recent.

Assessment of heterogeneity
We initially pooled all data with a fixed-effect model. We measured heterogeneity using the $I^2$ statistic (a measure of the degree of inconsistency between pooled studies). We used a random-effects model to determine the impact of the variation in the results on the overall effect estimate.

Assessment of reporting biases
We planned to investigate publication bias by visually inspecting a funnel plot if ten or more trials had been included in a single meta-analysis.

Data synthesis
We grouped outcomes relating to studies according to:
1. anticholinergic agents versus beta$_2$-agonists; and
2. anticholinergic agents versus combination of anticholinergic agents plus beta$_2$-agonists.
We pooled outcomes that were reported in the studies when possible, in accordance with primary and secondary outcomes.

Subgroup analysis and investigation of heterogeneity
We examined the influence of trial characteristics on the observed treatment effect. Assuming sufficient numbers of trials and the availability of necessary data, we described clinical heterogeneity with respect to treatment setting and asthma severity.
- Age: two to five years versus five to eighteen years.
- Co-interventions: with corticosteroids versus none.
- Different delivery methods of anticholinergics: metered dose inhaler (MDI) versus nebuliser.
- Duration of anticholinergics administration: less than seven days versus more than seven days duration.
- Asthma severity: mild and moderate versus severe asthma.
Sensitivity analysis

Sensitivity analyses provide an approach for testing how robust the results of a review are relative to key decisions and assumptions that have been made in the process of conducting the review. We planned to investigate the overall study quality of the pooled result using the Cochrane approach.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies.

Results of the search are summarised below.

Results of the search

Of the 349 abstracts that we identified, we retrieved 81 papers for full assessment by the reviewers (LT and AC). After excluding articles that focused on adult patients or articles that did not use inhaled anticholinergics as single agents for comparison (see Characteristics of excluded studies for reasons for exclusion), seven studies (one paper was an abstract from a conference proceeding of a paper (Van Bever 1994)) from six trials met the inclusion criteria for the review (Cook 1985; Guill 1987; Watson 1988; Van Bever 1994; Calvo 1998; Ni 2003). See 'Characteristics of included studies' for full details on each study.

Included studies

Study design

All studies were randomised and double-blind except Ni 2003. All studies were of a parallel group design.

Participants

The included studies involved children between the ages of two and eighteen years who were treated for acute asthma. These studies recruited patients mainly from the emergency room (Cook 1985; Guill 1987). Van Bever 1994 and Watson 1988 did not refer to the study setting. Cook 1985 and Watson 1988 included patients with moderately severe asthma. Guill 1987 included patients of any severity of acute asthma and used episodes of wheezing for randomisation rather than individual patients. Calvo 1998 recruited participants who did not require hospitalisation and whose peak expiratory flow (PEF) was less than 80%. Symptom scores indicated that participants were suffering from moderately severe acute asthma (Calvo 1998).

Interventions

Route/Delivery

Three studies used nebulisers to deliver therapy (Cook 1985; Guill 1987; Watson 1988). These studies utilised a Hudson nebuliser with face mask but different models and techniques for driving therapy. Cook 1985 used an oxygen (8 litres/min) driven nebuliser unit and Watson 1988 used an air (7 litres/min) driven nebuliser. Guill 1987 did not describe the driving gas for the nebuliser. Ni 2003 used an oxygen driven nebuliser but no further details were available (translated paper). Calvo 1998 and Van Bever 1994 used a holding chamber and MDI.

Type of drug/dosage

Differing drugs, doses and dosing regimens were used in the six studies.

Calvo 1998: Three groups (ipratropium versus salbutamol versus ipratropium + salbutamol). Salbutamol 100 mcg (two inhalations; total 200 mcg per dose) four times in the first hour and three times in the subsequent hour at regular intervals, versus ipratropium bromide 20 mcg (two inhalations; total 40 mcg per dose) at the same time-points versus combination salbutamol and ipratropium (equivalent doses to the parallel component therapies) at the same time-points. Also, Calvo 1998 allowed for the addition of inhaled salbutamol or oral steroids where participants were deemed poor responders to therapy.

Cook 1985: Three groups (ipratropium versus fenoterol versus ipratropium + fenoterol). 0.025% (250 mcg/mL) solution of ipratropium bromide versus 0.5% (5000 mcg/mL) fenoterol solution versus combination 0.025% (250 mcg/mL) ipratropium bromide and 0.5% (5000 mcg/mL) fenoterol. The doses of both fenoterol and ipratropium bromide solution were adjusted according to the age of the children.

Guill 1987: Three groups (atropine versus metaproterenol versus atropine + metaproterenol). Atropine sulfate (0.05 to 0.1 mg/kg i.e. 500 to 1000 mcg/kg) versus 5% (50,000 mcg/mL) metaproterenol versus combination (5% metaproterenol and atropine sulfate). The dose of metaproterenol was adjusted to age and the dose of atropine sulfate was adjusted to weight.

Ni 2003: Three groups (ipratropium versus salbutamol versus ipratropium + salbutamol). 0.5% (5000 mcg/mL) salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg) versus 0.025% (250 mcg/mL) ipratropium bromide (0.25 to 1 mL i.e. 62.5 to 250 mcg) versus combination (salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg) and ipratropium bromide (0.25 to 1 mL i.e. 62.5 to 250 mcg)). The dose of both salbutamol and ipratropium bromide solution were adjusted according to the age of the children.

Van Bever 1994: Two groups (oxitropium versus fenoterol). Oxitropium bromide 200 mcg versus fenoterol 200 mcg. Subse-
quently all patient received 400 mcg fenoterol in an open label study.

Watson 1988: Three groups (ipratropium versus fenoterol versus ipratropium + fenoterol). Ipratropium bromide 250 mcg versus fenoterol 625 mcg versus combination (ipratropium bromide 250 mcg plus fenoterol 625 mcg).

**Measurements of outcomes**

Outcomes measured differed between the studies. For an overview of the outcomes measured in the studies, please see Table 1. Definition of treatment failure varied between the studies. Guill 1987 considered three criteria for treatment failure (return visit to the emergency department within 12 to 24 hours; intravenous (IV) treatment; or admission to hospital). Watson 1988 considered admission to hospital as treatment failure and Cook 1985 set IV therapy as indication of treatment failure. Calvo 1998 did not report any pre-defined treatment failure criteria, although this study reported that treatment was stopped if the TAL score was less than 2, if there was a poor response to the therapy and/or PEF was less than 15% at first measurement or if there was intolerance to the treatment (TAL score is a clinical scoring system based on several markers such as respiratory rate, wheezing and cyanosis; the scale runs from 0 to 12, where 12 indicates a very severe illness; Tal 1983). Poor response to therapy was defined in terms of change in PEF + 4% or less.

Four of the included studies used symptom scores: Calvo 1998 measured symptoms on the TAL scale; Watson 1988 and Guill 1987 used pulmonary index which used a scale of 0 to 12; and Cook 1985 used a clinical score on an in-house four-point scale. Cook 1985 and Guill 1987 measured repeat nebulisations as one of their outcome measures. Watson 1988 did not measure additional medication. Calvo 1998 measured need for additional bronchodilation and steroid therapy. Guill 1987 used improvement in PEF as one of their objective measures, while Watson 1988 elaborately measured spirometric functions (forced expiratory volume in 1 second (FEV₁), forced expiratory flow at the 25 to the 75% point of forced vital capacity (FEF₂⁵₋₇⁵) and forced vital capacity (FVC)), at various time intervals to monitor the change. In addition to the improvement in the oxygen saturations, Watson 1988 also determined whether bronchodilation was still possible after study medication had been given, by administering open label salbutamol and measuring spirometry.

**Excluded studies**

We excluded studies that focused on adult patients or that did not use inhaled anticholinergics as single agents for comparison (see Characteristics of excluded studies for reasons for exclusion).

**Risk of bias in included studies**

Our judgement on the risk of bias for included studies is summarised in Figure 1.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality item for each included study.
Allocation
We judged two studies to be at low risk of bias for random sequence generation (Guill 1987; Van Bever 1994). The randomisation method was less well described in four studies and we therefore judged them to be at unclear risk of bias (Cook 1985; Watson 1988; Calvo 1998; Ni 2003).

Blinding
We judged four studies to be at low risk of bias for blinding (Cook 1985; Guill 1987; Van Bever 1994; Calvo 1998), while we were unclear about the risk of bias in Watson 1988 and we judged Ni 2003 to be at high risk of bias.

Calvo 1998: Blinding and randomisation were referred to, but were not described. Participants were excluded from study entry if they required hospitalisation. No participants failed treatment and all were accounted for. The addition of salbutamol and/or oral steroids may have influenced the response to therapy across the three groups.

Cook 1985: This study is described as a double-blind trial although the method of double-blinding is not explicit. Three patients (one from each group) required IV therapy and did not complete the trial. Children of various age groups received different volumes of the medicines in their respective groups, however, there is no explanation of how this was done with the blinding intact.

Guill 1987: This study is described as a double-blind trial. Randomisation was done for each episode of wheezing, rather than for individual patients. Although the method of double-blinding is explicit, it is difficult to explain how blinding was preserved when subjects entered into the trial more than once and yet did not receive the same treatment more than once. Ten episodes of wheezing were classified as treatment failure, six of these were in the group which received atropine sulfate only.

Ni 2003: This study is an unblinded trial. No patients withdrew or dropped out. This paper was published in Chinese and translated.

Selective reporting
Outcomes measured differed between the studies. Outcome measures in each individual study were reported.

One study (Ni 2003) reported outcome measures as “no symptoms” or “improved symptoms” (shortness of breath, wheeze and hypoxia); no detailed description was available for outcome measures. Ni 2003 reported complete improvement in symptoms in 40 children and partial improvement in symptoms in 22 children in the group treated with salbutamol in combination with ipratropium bromide. However, only 55 children were allocated to this group. This paper was published in Chinese and translated.

Incomplete outcome data
Guill 1987 reported ten episodes of wheezing that were classified as treatment failure (two in the group which received metaproterenol only, six in the group which received atropine sulfate only and two in the group which received combination treatment). One study (Cook 1985) reported that three patients (one from each group) required IV therapy and did not complete the trial and hence we excluded the results of these patients from the analysis. Withdrawals were not reported in Van Bever 1994’s study. No detailed description was available for outcome measures in one study which was published in Chinese and translated; but no patients withdrew or dropped out (Ni 2003).

Other potential sources of bias
One study (Watson 1988) was supported by a grant from a pharmaceutical company. Two studies (Guill 1987; Van Bever 1994) received pharmaceutical company support for the medications.

Effects of interventions
Only data for anticholinergics versus beta2-agonists and anticholinergics versus anticholinergics plus beta2-agonists were available. We entered relevant data into forest plots but were only able to pool data for the outcomes of treatment failure and hospitalisation. We could not pool other data due to divergent outcome measurements, and different types of anticholinergic agents and bronchodilators used in the studies. Results are presented according to comparison and then by outcome, with the primary outcome listed first.

Anticholinergic agents versus beta2-agonists
We were able to include all six studies (Cook 1985; Guill 1987; Watson 1988; Van Bever 1994; Calvo 1998; Ni 2003) in this intervention. However insufficient data (translated paper) was available from Ni 2003 and hence we did not include data from this paper below.
Primary outcome: treatment failure (analysis 1.1)

There is variability in the definition of ‘treatment failure’, although all required additional treatment. One study reported admission data discreetly from treatment failure data (Watson 1988). The other four studies reported data on treatment failure according to their own pre-defined criteria (see Table 1). In one study (Calvo 1998), we considered treatment failure as those children who were poor responders to bronchodilator therapy (PEF + 4% or less). In another study (Cook 1985), we considered treatment failure as those children who required intravenous therapy as well as those who required repeat nebulizations of medications. In the study of Guill 1987 and colleagues, treatment failure was considered as those children who required repeat nebulizations of medications, those who either worsened after nebulized treatment and required alternative therapy (injectable epinephrine) or improved initially after one or two nebulized treatments but deteriorated within one hour and required hospitalisation. We could pool data from three studies that used similar medications (ipratropium versus beta2-agonist) (Cook 1985; Watson 1988; Calvo 1998). Pooled analysis revealed a (just) significant difference between the two groups with those who received ipratropium bromide more likely to have treatment failure compared to those on beta2-agonist (OR 2.36; 95% CI 1.02 to 5.47; Analysis 1.1). The addition of Guill 1987’s study (to the forest plot) that used atropine sulphate compared to metaproterenol (9/13 versus 8/15, respectively) further strengthened the efficacy of beta2-agonists compared to anticholinergic agents (OR 2.27; 95% CI 1.08 to 4.75) as depicted in Figure 2.

Figure 2. Forest plot of comparison: 1 Anticholinergic agents versus short-acting beta2-agonists, outcome: 1.1 Treatment failure.

### 1.1 Ipratropium bromide versus beta2-agonists

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Anticholinergic Events</th>
<th>Beta2 agonists Events</th>
<th>Total Events</th>
<th>Weight</th>
<th>Odds Ratio M-H, Fixed, 95% CI</th>
<th>Heterogeneity Chi², df (P)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calvo 1998</td>
<td>11</td>
<td>49</td>
<td>60</td>
<td>45.4%</td>
<td>2.15 [0.71, 6.53]</td>
<td>0.3, df = 2 (P = 0.88), P = 0%</td>
<td></td>
</tr>
<tr>
<td>Cook 1985</td>
<td>8</td>
<td>15</td>
<td>16</td>
<td>26.1%</td>
<td>2.20 [0.52, 9.30]</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Watson 1988</td>
<td>2</td>
<td>15</td>
<td>14</td>
<td>4.6%</td>
<td>5.34 [0.24, 121.0]</td>
<td>0.05, df = 2 (P = 0.84)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>21</td>
<td>72</td>
<td>73</td>
<td>76.1%</td>
<td>2.30 [0.02, 5.47]</td>
<td>0.05</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 21; Heterogeneity: Not applicable; Test for overall effect: Z = 0.05 (P = 0.96)

### 1.2 Atropine sulphate versus metaproterenol

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Anticholinergic Events</th>
<th>Beta2 agonists Events</th>
<th>Total Events</th>
<th>Weight</th>
<th>Odds Ratio M-H, Fixed, 95% CI</th>
<th>Heterogeneity Chi², df (P)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guill 1987</td>
<td>9</td>
<td>13</td>
<td>15</td>
<td>23.9%</td>
<td>1.87 [0.82, 4.22]</td>
<td>0.05, df = 1 (P = 0.03)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>13</td>
<td>15</td>
<td>28</td>
<td>23.9%</td>
<td>1.97 [0.82, 4.22]</td>
<td>0.05, df = 1 (P = 0.03)</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 18; Heterogeneity: Not applicable; Test for overall effect: Z = 2.17 (P = 0.03)

Primary outcome: hospital admissions (analysis 1.2)

Three studies (Guill 1987; Watson 1988; Calvo 1998) reported on this outcome but only two studies had children who required hospitalisation (Guill 1987; Watson 1988). No admissions occurred in the Calvo 1998 study. Pooled data from the two studies (Calvo 1998; Watson 1988) that used similar medications (ipratropium versus beta2-agonist) showed no significant difference between groups (OR 5.34; 95% CI 0.24 to 121.0). The addition of Guill 1987’s study (to the forest plot) that used atropine sulphate versus metaproterenol, revealed a significant difference between the two groups, with those who received anticholinergic agents more likely to result in a hospital admission compared to those on beta2-agonists (OR 5.50; 95% CI 1.11 to 27.16; Analysis 1.2).

Secondary outcome: symptom scores

Guill 1987 and Watson 1988 reported pulmonary index scores (composite scores of several outcome measures). Guill 1987 did not report a significant difference between treatment groups at first nebulisation. Watson 1988 reported that clinical scores improved significantly in all treatment groups at all times (no P values were reported).
Calvo 1998 reported data on TAL score from eight measurements over two hours. We only extracted data for the first 30 minutes due to concerns arising over the addition of a known bronchodilator if there was a lack of improvement after 30 minutes. For results taken up to 30 minutes for the three treatment groups, please see Table 1. Significant differences were observed at 15 and 30 minutes for salbutamol versus ipratropium bromide (at 30 minutes: 3.3 (standard deviation (SD) 1.1) versus 4.2 (SD 0.9); P < 0.01).

Cook 1985 measured symptoms on an in-house symptom score (see Table 1). No significant difference was reported between the treatment groups across the two hours of treatment on clinical rating.

**Secondary outcome: requirement for additional medication**

Calvo 1998, Cook 1985 and Guill 1987 measured the requirement for additional treatment in different ways (see Table 1).

Calvo 1998 reported no significant difference in the requirement for additional study medication between children on ipratropium and those on salbutamol (5.3 (SD 1.1) versus 4.7 (SD 1.2); P > 0.05) respectively. Furthermore, there was no significant difference in the requirement for corticosteroids at 60 minutes between children on ipratropium and those on salbutamol (0.3 (SD 0.4) versus 0.2 (SD 0.4) respectively; P > 0.05). There was a significant difference in terms of need for additional bronchodilators in the ipratropium group compared with salbutamol (1.7 (SD 2.1) versus 1.0 (SD 1.8); P < 0.05).

Cook 1985 reported the number of repeat nebulisations required. No statistically significant differences were observed between treatment groups.

Guill 1987 reported the number of treatments required. More participants in the metaproterenol group (7/15) could be discharged after fewer treatments than those in the atropine group (4/13). No P value was reported for the metaproterenol group versus the atropine group.

**Secondary outcome: lung function**

Data are presented by outcome (PEF and FEV\textsubscript{1}) and then by study. We have extracted and presented data for outcome assessment at 30 and 120 minutes where possible. We consider these time-points to be the most clinically relevant in an asthma attack. P values are presented from the published papers; some of these considered data at all time-points.

**PEF (percentage predicted)**

Calvo 1998 reported no significant difference between salbutamol (80.5 (SD 7)) and ipratropium (78.1 (SD 7.3)); P > 0.05 at 30 minutes (Analysis 1.3). We did not extract subsequent data due to the potential for confounding by the introduction of concomitant therapy in all groups.

Guill 1987 reported lung function at 20 to 30 minutes after treatments were administered. We extracted data for lung function taken after the first administration which corresponds approximately to 30 minute data. We did not observe any significant differences between the groups at 30 (Analysis 1.3) minutes. We did not include data extracted for subsequent lung function measurement in the review as they represented assessment 20 to 30 minutes after a second treatment, and 40 to 60 minutes after the first treatment.

**FEV\textsubscript{1}**

Watson 1988 reported non-significant differences when data were analysed as absolute change in FEV\textsubscript{1} and percentage change from baseline. When Watson 1988 and colleagues analysed data as change in percentage predicted, fenoterol was significantly better than ipratropium alone (P = 0.02, at each time-point).

Absolute scores at 30 minutes were: ipratropium group 1.51 (SD 0.84) and fenoterol group 1.86 (SD 0.85) (Analysis 1.5). Absolute scores at 120 minutes were: ipratropium group 1.48 (SD 0.8) and fenoterol group 1.89 (SD 0.89) (Analysis 1.7).

Van Bever 1994 reported lung function at 20 minutes after treatments were administered. A significant improvement in FEV\textsubscript{1} in both groups (i.e. children on oxitropium bromide and those on fenoterol) compared to baseline (82.9 SD (9.6); P 0.003). A significant improvement in FEV\textsubscript{1} was observed after administration of 200 mcg oxitropium bromide or fenoterol and subsequent administration of 400 mcg of fenoterol (87.2 (SD 11.0); P 0.03).

**FEF\textsubscript{25−75}**

One study (Watson 1988) reported results for FEF\textsubscript{25−75} for the comparison of ipratropium with fenoterol. There was a significant difference between fenoterol and ipratropium in FEF\textsubscript{25−75} whether considered as absolute change or as change in percentage predicted (P < 0.05, no time-point specified).

Absolute scores at 30 minutes were: ipratropium group 0.92 (SEM 0.15) and fenoterol group 1.40 (SEM 0.22). Absolute scores at 120 minutes were: ipratropium group 0.94 (SEM 0.13) and fenoterol group 1.56 (SEM 0.25).

**Secondary outcome: pulse oximetry**

Watson 1988 reported that there was no significant difference between the two groups for pulse oximetry. However, there was a significant improvement in oxygen saturation in the fenoterol group at 30 minutes which continued throughout the study (no P value reported). The improvement in oxygen saturation for ipratropium alone was not statistically significant at 30 minutes, but was so at 60 minutes and thereafter (no P values reported).
Secondary outcome: withdrawals
No withdrawals occurred in three studies (Watson 1988; Calvo 1998; Ni 2003). Three children dropped out from one study (Cook 1985; one from each group). Guill 1987 reported the number of treatment failures. Because the primary outcome was the number of additional treatments required before clinical improvement was observed, participants only contributed data for subsequent clinical assessment if they had not improved subsequent to the previous treatment; withdrawals were not therefore measured. Van Bever 1994 did not report on withdrawals.

Secondary outcome: side effects
All studies reported no significant differences in side effects between the participants.

Anticholinergic agents versus combination of anticholinergic agents + beta-agonists

Primary outcome: treatment failure (analysis 2.1)
Four studies reported data on treatment failure according to their own pre-defined criteria (see Table 1). In one study (Calvo 1998), we considered treatment failure as those children who were poor responders to bronchodilator therapy (PEF + 4% or less). In another study (Cook 1985), we considered treatment failure as those children who required intravenous therapy as well as those who required repeat nebulizations of medications. In one study (Guill 1987), we considered treatment failure as those children who required repeat nebulizations of medications, those who either worsened after nebulized treatment and required alternative therapy (injectable epinephrine) or improved initially after one or two nebulized treatments but deteriorated within one hour and required hospitalization. We were able to pool data from three studies that used similar medications (ipratropium versus beta2-agonist plus ipratropium) (Cook 1985; Watson 1988; Calvo 1998). A significant difference between anticholinergic and combination therapy was observed (OR 3.67; 95% CI 1.41 to 9.50; Analysis 2.1) i.e. those who received ipratropium alone were more likely to have treatment failure compared to those on combination therapy. Guill 1987 reported that 2 out of 16 participants failed treatment in the combination (atropine and metaproterenol) group (P < 0.02) versus atropine sulfate alone. Combining these studies (anticholinergics alone versus anticholinergic agents + beta2-agonists), those who received anticholinergics alone were significantly more likely to experience treatment failure compared to those who received anticholinergic + beta2-agonists, Figure 3 (OR 2.65; 95% CI 1.20 to 5.88).

Figure 3. Forest plot of comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, outcome: 2.1 Treatment failure.
Primary outcome: admission to hospital (analysis 2.2)

Three studies (Guill 1987; Watson 1988; Calvo 1998) reported on this outcome but only two studies had children who required hospitalisation (Guill 1987; Watson 1988). Pooled data from the two studies that used similar medications (ipratropium versus beta2-agonist plus ipratropium) showed no significant difference between groups (OR 5.69; 95% CI 0.25 to 128.5; Analysis 2.2). The addition to the forest plot of Guill 1987’s study that used atropine sulfate versus atropine sulfate and metaproterenol, revealed a significant difference between the two groups with those who received anticholinergic agents more likely to result in a hospital admission compared to those on combination therapy (OR 5.90; 95% CI 1.20 to 29.05).

Secondary outcome: symptom scores

Guill 1987 and Watson 1988 reported pulmonary index scores. Guill 1987 did not report a significant difference between treatment groups at first nebulisation. Watson 1988 reported that clinical scores improved significantly in all treatment groups at all times (no P values were reported). Calvo 1998 reported data on TAL score from eight measurements over two hours. We extracted data only for the first 30 minutes due to concerns arising over the addition of a known bronchodilator if there was a lack of improvement after 30 minutes. For results taken up to 30 minutes for the three treatment groups, please see Table 2. Significant differences were observed at 15 and 30 minutes for combination therapy versus ipratropium (at 30 minutes 2.8 (SD 1.0) versus 4.2 (SD 0.9); P < 0.01). Cook 1985 measured symptoms on an in-house symptom score (see Table 1). No difference was reported between the treatment groups across the two hours of treatment on clinical rating.

Secondary outcome: requirement for additional medication

Calvo 1998, Cook 1985 and Guill 1987 measured the requirement for additional treatment in different ways (see Table 1). Calvo 1998 reported a significant difference between combination therapy and ipratropium in terms of study medication requirement (3.7 (SD 1.1) versus 5.3 (SD 1.1) respectively; P < 0.01) and bronchodilator requirement (0.5 (SD 1.3) versus 1.7 (SD 2.1) respectively; P < 0.01). There was a non-significant difference between combination and ipratropium in terms of corticosteroid requirement (0.1 (SD 0.3) versus 0.3 (SD 0.4) respectively; P > 0.05). Cook 1985 reported the number of repeat nebulisations required. No statistically significant differences were observed between treatment groups. Guill 1987 reported the number of treatments required. More participants in the metaproterenol and combination groups could be discharged after fewer treatments than those in the atropine group (atropine group 4/13; combination group 5/16). No P values were reported for the combination group versus atropine group.

Secondary outcome: lung function

Data are presented by outcome (PEF and FEV1) and then by study. We have extracted and presented data for outcome assessment at 30 and 120 minutes where possible. We consider these time-points to be the most clinically relevant in an asthma attack. P values are presented from the published papers; some of these considered data at all time-points.

PEF (percentage predicted)

Two studies (Guill 1987; Calvo 1998) reported PEF percentage predicted. Calvo 1998 reported a significant difference between the combination (85.1 (SD 6.7)) and ipratropium groups (78.1 (SD 7.3)); P < 0.01 at 30 minutes (Analysis 2.4). We did not extract subsequent data due to the potential for confounding by the introduction of concomitant therapy in all groups. Guill 1987 reported lung function at 20 to 30 minutes after treatments were administered. We extracted data for lung function taken after the first administration which corresponds approximately to 30 minute data. No significant differences were observed between the groups. We did not include data extracted for subsequent lung function measurement in the review as they represented assessment 20 to 30 minutes after a second treatment, and 40 to 60 minutes after the first treatment.

FEV1

Watson 1988 reported a significant difference between combination and ipratropium alone in terms of absolute change, (P = 0.005, all time-points), change in percentage predicted (P = 0.0002, all time-points; Analysis 2.6) and percentage change from baseline (P = 0.002, all time-points). All data were presented graphically. Absolute scores at 30 minutes were: combination group 1.94 (SD 0.93) and ipratropium group 1.51 (SD 0.84) (Analysis 2.6). Absolute scores at 120 minutes were: combination group 2.11 (SD 1.05) and ipratropium group 1.48 (SD 0.8) (Analysis 2.7).

FEF25–75

One study (Watson 1988) reported this. A significant difference in FEF25–75 was reported between the combination and ipratropium group (P < 0.005, no time-point specified). Absolute scores at 30 minutes were: combination group 1.57 (SEM: 0.25) and ipratropium group: 0.92 (SEM 0.15). Absolute scores at 120 minutes were: combination group 1.82 (SEM: 0.3) and ipratropium group: 0.94 (SEM 0.13).

Secondary outcome: pulse oximetry

Watson 1988 reported that there were no significant differences between the three groups. However, there was a significant improvement in oxygen saturation in the combination and fenoterol groups at 30 minutes which continued throughout the study (no P values reported).
Secondary outcome: withdrawals
No withdrawals occurred in three studies (Watson 1988; Calvo 1998; Ni 2003). Three children dropped out from one study (Cook 1985; one from each group). Guilla 1987 reported the number of treatment failures. Because the primary outcome was the number of additional treatments required before clinical improvement was observed, participants only contributed data for subsequent clinical assessment if they had not improved subsequent to the previous treatment; withdrawals were not therefore measured. Van Bever 1994 also did not report on withdrawals.

Secondary outcome: side effects
All studies reported no significant differences in side effects between the participants.

Discussion
In this review, we evaluated the trials that studied the efficacy of ipratropium bromide given alone or in combination with beta2-agonists (compared to a control of beta2-agonists) for acute asthma in children aged over two years. Despite an extensive and thorough literature search in which we found hundreds of papers examining anticholinergic drugs, only seven studies (one paper was an abstract from a conference proceedings of a paper (Van Bever 1994)) from six trials met the inclusion criteria for the review.

Summary of main results
We found that inhaled anticholinergic agents as single agent bronchodilators were less efficacious (i.e. led to more treatment failure) than beta2-agonists in children over the age of two years with acute asthma exacerbations. Anticholinergics were also less efficacious (i.e. led to more treatment failure) than anticholinergics combined with beta2-agonists. In this review, data on clinical scores/symptoms that were measured on different scales were variable but all generally showed that ipratropium bromide used alone was less efficacious compared to beta2-agonists or combined with beta2-agonists. Also, individual trials reported that lung function was superior in the combination group when compared to anticholinergic agents.

In our review, there was no significant increase in the occurrence of tachycardia, tremor, mydriasis or dryness of oral mucous membranes observed among participants treated with anticholinergic agents. Ipratropium bromide has no or very little systemic toxicity. Another significant advantage to ipratropium bromide in the critically ill asthma patient is the lack of increase in heart rate, which does occur with beta2-agonist use (Cugell 1986). The only remarkable reported side effect in the literature is the inhibition of salivary secretions at high doses. When nebulised, ipratropium is very unlikely to affect urinary flow or intraocular tension, and possible effects on the eye (i.e. glaucoma) can be prevented by using a mouthpiece during nebulisation. Although data is not available in children, the speed of onset of effect is reported in adults with airway disease to be 3 to 30 minutes with up to 50% of the response occurring in three minutes and 80% in 30 minutes, with a peak bronchodilator effect observed within one to two hours, and duration of action of up to approximately six hours (Gross 1988).

Overall completeness and applicability of evidence
Our thorough systematic search for published and unpublished trials resulted in identification of important trials. We could only extract data from six trials. Despite the small number of studies, we conclude from the studies that inhaled anticholinergic drugs as single agent bronchodilators were less efficacious than beta2-agonists and anticholinergics combined with beta2-agonists.

Quality of the evidence
This systematic review was limited by the quality of existing data. In addition, there was clinical heterogeneity amongst the trials and we could not pool some data due to divergent outcome measurements and different types of anticholinergic agents and bronchodilators used in the studies. The number (i.e. six trials) and size of studies pooled were small. There were limited data on hospital admissions.

Potential biases in the review process
The studies were generally small with potential risk of bias as shown in Figure 1.

Agreements and disagreements with other studies or reviews
Inhaled anticholinergics in combination with beta2-agonists is now the standard recommended treatment for children with acute moderate to severe asthma exacerbations.

Authors’ conclusions
Implications for practice
In children over the age of two years with acute asthma exacerbations, inhaled anticholinergic drugs as single agent bronchodilators were less efficacious than beta2-agonists. Inhaled anticholinergics on their own were also less efficacious than anticholinergics.
combined with beta2-agonists. Thus in children over the age of two years with acute asthma exacerbations, inhaled anticholinergics alone are not appropriate as a single agent. None of the major asthma guidelines currently recommend inhaled anticholinergics as a single agent and our review supports this. The use of anticholinergics was not found to be associated with significant side effects such as tachycardia, tremor, mydriasis or dryness of oral mucous membranes.

Implications for research

Inhaled anticholinergics combined with beta2-agonists is now the standard recommended treatment in guidelines for children with acute moderate to severe asthma exacerbations. Thus, in light of our conclusion above, we do not recommend any further trials comparing inhaled anticholinergics as a single agent in children with acute asthma exacerbations.

ACKNOWLEDGEMENTS

We thank Elizabeth Stovold and Susan Hansen from the Cochrane Airways Group for performing the searches and obtaining the relevant articles. We also thank Toby Lasserson for the support in the protocol development and review of the manuscript. We also thank the Australian Cochrane Airways Group for providing Dr Teoh a scholarship.

REFERENCES

References to studies included in this review

Calvo 1998 (published data only)

Cook 1985 (published data only)

Guill 1987 (published data only)

Ni 2003 (published data only)

Van Bever 1994 (published data only)

Watson 1988 (published data only)
Wade TA, Watson MD, Becker AB, Simons FER. Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy and Clinical Immunology 1988;82:1012–8.

References to studies excluded from this review

Beck 1985 (published data only)

Benito Fernandez 2000 (published data only)

Bratteby 1986 (published data only)

Browne 2002 (published data only)

Craven 2001 (published data only)

De Stefano 1990 (published data only)

Ducharme 1998 (published data only)
Anticholinergic therapy for acute asthma in children (Review)

Ferres 1988 (published data only)

Goggin 2001 (published data only)

Hayday 2002 (published data only)

Iramain 2011 (published data only)

Lew 1990 (published data only)

Lin 1978 (published data only)

Mallol 1987 (published data only)

Mirsadraee 2009 (published data only)

Monge 2000 (published data only)

Pulejo 1986 (published data only)

Qureshi 1997 (published data only)

Qureshi 1998 (published data only)

Rayner 1987 (published data only)

Reisman 1988 (published data only)

Schub 1995 (published data only)

Storms 1986 (published data only)

Storr 1986 (published data only)

Timsit 2002 (published data only)

Ulrik 1992 (published data only)

Ward 1981 (published data only)

Ward 1985 (published data only)
Yeung 1980 (published data only)

Youngchaiyud 1989 (published data only)

Zimmerman 1984 (published data only)

Zorc 1999 (published data only)

Additional references

Beakes 1997

Brown 2001

BTS 2009

Cagell 1986

Everard 2005

Gross 1988

Higgins 2011

McDonald 2010

NAC 2006

NHLBI 2007

Plotnick 2008

RevMan 2011

Rodrigo 2002

Tal 1983

Undem 2001

* Indicates the major publication for the study
### Characteristics of included studies  
#### [ordered by study ID]

**Calvo 1998**

| Methods
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomised, double-blind parallel group trial. Method of randomisation not reported</td>
</tr>
</tbody>
</table>

| Participants
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 120 (Group 1: 40; Group 2: 40; Group 3: 40). 73 M/47 F. Mean age 7.3 years (age range: 5 to 14 years). No withdrawals occurred and all participants were accounted for</td>
</tr>
<tr>
<td>• Inclusion criteria: age between 5 and 14 years; acute asthma attack; aerochamber well used; able to use peak flow meter; PEF &lt; 80% predicted; TAL score &gt; 0 on 5-point scale.</td>
</tr>
<tr>
<td>• Exclusion criteria: cardiac failure; lung disease; need for hospitalisation; first acute episode of acute bronchial obstruction; hypersensitivity to trial medications; treatment &lt; 8 hours prior to study entry</td>
</tr>
</tbody>
</table>

| Interventions
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>All treatments were administered by aerochamber</td>
</tr>
<tr>
<td>• Group 1: salbutamol 100 mcg per inhalation</td>
</tr>
<tr>
<td>• Group 2: ipratropium bromide 20 mcg per inhalation</td>
</tr>
<tr>
<td>• Group 3: salbutamol 100 mcg per inhalation and ipratropium bromide 20 mcg per inhalation</td>
</tr>
<tr>
<td>2 inhalations 4 times in first hour, 2 inhalations 3 times in second hour</td>
</tr>
</tbody>
</table>

| Outcomes
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PEF; TAL score; need for additional treatment (salbutamol and oral steroids)</td>
</tr>
</tbody>
</table>

| Notes
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial protocol allowed for addition of salbutamol (100 mcg per inhalation, 2 inhalations after each control) to trial medicines if participants showed no response (clinical or PEF) at 30 minutes or corticosteroid therapy at 60 minutes</td>
</tr>
</tbody>
</table>

#### Risk of bias

| Bias
| Authors' judgement | Support for judgement |
| --- | --- | --- |
| Random sequence generation (selection bias) | Unclear risk | Not reported |
| Allocation concealment (selection bias) | Unclear risk | Not reported |
| Blinding (performance bias and detection bias) All outcomes | Low risk | Double-blind |
### Cook 1985

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised double-blind parallel group trial. Method of randomisation not reported Emergency Department setting No intention to treat population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>N = 48 (Group 1: 16; Group 2: 16; Group 3: 16). 26 M/22 F. Mean age 6.6 years (age range 18 months to 12 years). 3 withdrawals due to requirement of IV therapy (1 from each group) • Inclusion criteria: moderately severe acute asthma based on clinical presentation • Exclusion criteria: patients deemed to require IV therapy</td>
</tr>
<tr>
<td>Interventions</td>
<td>All treatments were administered via a Hudson nebuliser driven by oxygen (flow rate 8 L/min) • Group 1: ipratropium bromide (0.025%) 1 mL i.e. 250 mcg (1 to 4 years); 1.5 mL i.e. 375 mcg (5 to 8 years); 2 mL i.e. 500 mcg (9 to 12 years) • Group 2: fenoterol (0.5%) 0.125 mL i.e. 625 mcg (1 to 4 years); 0.25 mL i.e. 1250 mcg (5 to 8 years); 0.5 mL i.e. 2500 mcg (9 to 12 years) • Group 3: ipratropium bromide + fenoterol (same dosage as above) Duration 2 hours. Repeat nebulisations at 2-hourly intervals until stable enough to return to inhaled or oral medication</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Repeat nebulisation; pulse rate; respiratory rate; clinical rating of wheeze; air entry; respiratory distress; overall index of response to treatment</td>
</tr>
<tr>
<td>Notes</td>
<td>Plotnick and Ducharme contacted trialists and established that allocation concealment was adequate Different volumes of trial medication were given according to age of the participants in each treatment group. The trial was described as 'double-blind' and it was not reported how the blinding of the trialists to the treatment was maintained</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>Low risk</td>
<td>All doses administered blind</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Guill 1987

| Methods | Randomised double-blind parallel group trial. Method of randomisation: computer-generated random numbers table  
Emergency department or outpatient setting |
|---------|--------------------------------------------------------------------------------------------------|
| Participants | $N = 35$ with $44$ episodes of acute asthma (Group 1: $15$; Group 2: $13$; Group 3: $16$)  
$26$ M/$18$ F; age range: $13$ months to $13$ years |
| Interventions | All treatments were administered via a Hudson 1700 updraft nebuliser and paediatric face mask attached with standard oxygen tubing to a Pulmo-Áid compressor  
- Group 1: metaproterenol $5\%$ ($50,000$ mcg/mL), $0.2$ mL ($10,000$ mcg) in $< 12$ years; $0.3$ mL ($15,000$ mcg) $\geq 12$ years in $2$ mL normal saline  
- Group 2: atropine sulfate $0.05$ to $0.1$ mg/kg, max $2.0$ mg i.e. $500$ to $1000$ mcg/kg in $2$ mL normal saline  
- Group 3: metaproterenol + atropine sulfate (same dosage as above)  
Three doses of nebulised medicines were administered $20$ to $30$ minutes apart |
| Outcomes | - Severity of bronchospasm as assessed by a pulmonary index score ($0$ to $12$) at entry and $20$ minutes after each inhalation  
- PEF measure at entry and at $20$ minutes after each inhalation (in patients old enough to perform manoeuvre)  
- Number of treatments and treatment failure |
| Notes | Computer generated random numbers were used for each episode rather than for individual patients |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer generated random numbers</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Randomly assigned in a double-blind manner</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>Low risk</td>
<td>Double-blinded</td>
</tr>
</tbody>
</table>

### Ni 2003

| Methods | Randomised unblinded parallel group trial. Method of randomisation not reported  
Inpatient setting |
|---------|--------------------------------------------------------------------------------------------------|
| Participants | $N = 141$ (Group 1: $55$; Group 2: $48$; Group 3: $38$)  
No withdrawals occurred and all participants were accounted for  
$75$ M/$66$ F  
Age range: $1$ to $12$ years  
- Inclusion criteria: age between $1$ and $12$ years admitted with acute asthma |
Ni 2003  (Continued)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>All treatments were administered via a nebuliser</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Group 1: salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg) + ipratropium bromide (0.25 to 1 mL i.e. 62.5 to 250 mcg) diluted to 2 mL with normal saline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Group 2: 0.5% salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg) diluted to 2 mL with normal saline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Group 3: 0.025% ipratropium bromide (0.25 to 1 mL i.e. 62.5 to 250 mcg) diluted to 2 mL with normal saline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nebulised medications were administered 2 to 4 times a day</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Outcomes | No symptoms or improved symptoms (shortness of breath, wheeze and hypoxia) |
| Notes | Translated paper |

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>No details</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No details</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>High risk</td>
<td>Not double-blinded</td>
</tr>
</tbody>
</table>

Van Bever 1994

| Methods | Randomised double-blind parallel group trial. Method of randomisation: computerised random function choosing 10 numbers from 1 to 20, subsequently open study design Setting not reported |
| Participants | All treatments were administered via blinded metered dose inhalers with aerospheric N = 20; 15 M/5 F Mean age: 12.7 years (age range: 4.9 to 15.1 years) • Inclusion criteria: children with asthma with mild bronchoconstriction and FEV₁ between 50% and 85%; able to perform lung function tests and use a MDI with spacer appropriately; discontinued bronchodilators > 12 hours prior to study entry • Exclusion criteria: not available |
| Interventions | • Group 1: oxitropium bromide 200 mcg • Group 2: fenoterol 200 mcg Subsequently all patient received 400 mcg fenoterol in an open label study |
| Outcomes | Lung function: FEV₁; VC; MEF50; MEF25; medication side effects |

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Van Bever 1994 (Continued)

#### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computerised random numbers</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No details</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>Low risk</td>
<td>Blinded metered dose inhalers</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Watson 1988

#### Methods

Randomised double-blind parallel group trial. Method of randomisation not reported
Setting not reported

#### Participants

- N = 47 (Group 1: 16; Group 2: 15; Group 3: 16)
- Age range: 6 to 17 years
  - Inclusion criteria: exacerbation of acute asthma, able to perform forced expiratory manoeuvre, FEV₁ 30% to 70% predicted
  - Exclusion criteria: mild asthma or very severe acute asthma attack with actual or impending respiratory failure, known hypersensitivity to sympathomimetic or atropinic compounds, if patient had disorders other than asthma, allergic rhinitis, atopic dermatitis or prior use of an inhaled bronchodilator within 5 hours of study entry

#### Interventions

- Group 1: ipratropium bromide 250 mcg + fenoterol hydrobromide 625 mcg diluted to 4 mL isotonic solution
- Group 2: fenoterol 625 mcg diluted to 4 mL isotonic solution
- Group 3: ipratropium bromide 250 mcg diluted to 4 mL isotonic solution
  - All treatments were administered via a Hudson nebuliser driven by 7 L/min of room air.
  - Two doses of inhalations were given 60 minutes apart

#### Outcomes

- Clinical scores at 30, 60, 90 and 120 min
- Oxygen saturation at 30, 60, 90 and 120 min
- Spirometry at 30, 60, 90 and 120 min and after nebulised salbutamol
- Medication side effects

#### Notes

- No mention of the method of randomisation
- At end of study, albuterol 0.5% (5000 mcg/mL) (i.e. 0.02 mL/kg (100 mcg/kg)), max 1 mL (5000 mcg), diluted to 2 mL with normal saline) was administered in an open fashion to assess for possible additional bronchodilatation

### Risk of bias

---

_Anticholinergic therapy for acute asthma in children (Review)_

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beck 1985</td>
<td>RCT: Beta$_2$-agonist compared with combination anticholinergic and beta$_2$-agonist therapy</td>
</tr>
<tr>
<td>BenitoFernandez 2000</td>
<td>RCT: Beta$_2$-agonist compared with combination anticholinergic and beta$_2$-agonist therapy</td>
</tr>
<tr>
<td>Bratteby 1986</td>
<td>Non-RCT and chronic asthma. Beta$_2$-agonist compared with combination anticholinergic and beta$_2$-agonist therapy</td>
</tr>
<tr>
<td>Browne 2002</td>
<td>Control group did not fulfil criteria. RCT: Beta$_2$-agonist compared with combination anticholinergic and beta$_2$-agonist therapy</td>
</tr>
<tr>
<td>Craven 2001</td>
<td>Control group did not fulfil criteria. RCT: Beta$_2$-agonist compared with combination anticholinergic and beta$_2$-agonist therapy</td>
</tr>
<tr>
<td>De Stefano 1990</td>
<td>Chronic asthma. Beta$_2$-agonist compared with combination anticholinergic and beta$_2$-agonist therapy</td>
</tr>
<tr>
<td>Ducharme 1998</td>
<td>Control group did not fulfil criteria. RCT: Beta$_2$-agonist compared with combination anticholinergic and beta$_2$-agonist therapy</td>
</tr>
<tr>
<td>Ferres 1988</td>
<td>Children were aged less than 1 year</td>
</tr>
<tr>
<td>Goggin 2001</td>
<td>Control group did not fulfil criteria. RCT: Beta$_2$-agonist compared with combination anticholinergic and beta$_2$-agonist therapy</td>
</tr>
<tr>
<td>Year</td>
<td>Study Type</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>Hayday 2002</td>
<td>RCT</td>
</tr>
<tr>
<td>Iramain 2011</td>
<td>RCT</td>
</tr>
<tr>
<td>Lew 1990</td>
<td>RCT</td>
</tr>
<tr>
<td>Lin 1978</td>
<td>RCT</td>
</tr>
<tr>
<td>Mallol 1987</td>
<td>RCT</td>
</tr>
<tr>
<td>Mirsadraee 2009</td>
<td>RCT</td>
</tr>
<tr>
<td>Monge 2000</td>
<td>RCT</td>
</tr>
<tr>
<td>Pulejo 1986</td>
<td>RCT</td>
</tr>
<tr>
<td>Qureshi 1997</td>
<td>RCT</td>
</tr>
<tr>
<td>Qureshi 1998</td>
<td>RCT</td>
</tr>
<tr>
<td>Rayner 1987</td>
<td>RCT</td>
</tr>
<tr>
<td>Reisman 1988</td>
<td>RCT</td>
</tr>
<tr>
<td>Schuh 1995</td>
<td>RCT</td>
</tr>
<tr>
<td>Storms 1986</td>
<td>RCT</td>
</tr>
<tr>
<td>Stoor 1986</td>
<td>RCT</td>
</tr>
<tr>
<td>Timsit 2002</td>
<td>RCT</td>
</tr>
<tr>
<td>Ulrik 1992</td>
<td>Chronic asthma</td>
</tr>
<tr>
<td>Ward 1981</td>
<td>Non-RCT: mainly adult study</td>
</tr>
</tbody>
</table>
Continued

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ward 1985</td>
<td>RCT: mainly adult study</td>
</tr>
<tr>
<td>Yeung 1980</td>
<td>Exercise induced asthma</td>
</tr>
<tr>
<td>Youngchaiyud 1989</td>
<td>RCT: adult study</td>
</tr>
<tr>
<td>Zimmerman 1984</td>
<td>RCT: Chronic asthma</td>
</tr>
<tr>
<td>Zorc 1999</td>
<td>Control group did not fulfil criteria. RCT: beta-agonist compared with combination anticholinergic and beta-agonist therapy</td>
</tr>
</tbody>
</table>

RCT: randomised controlled trial
## Data and Analyses

### Comparison 1. Anticholinergic agents versus short-acting beta2-agonist

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Treatment failure</td>
<td>4</td>
<td>171</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>2.27 [1.08, 4.75]</td>
</tr>
<tr>
<td>1.1 Ipratropium bromide versus beta2-agonists</td>
<td>3</td>
<td>143</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>2.36 [1.02, 5.47]</td>
</tr>
<tr>
<td>1.2 Atropine sulphate versus metaproterenol</td>
<td>1</td>
<td>28</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>1.97 [0.42, 9.32]</td>
</tr>
<tr>
<td>2 Admission to hospital</td>
<td>3</td>
<td>139</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>5.50 [1.11, 27.16]</td>
</tr>
<tr>
<td>2.1 Ipratropium bromide versus beta2-agonist</td>
<td>2</td>
<td>111</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>5.34 [0.24, 121.00]</td>
</tr>
<tr>
<td>2.2 Atropine sulphate versus metaproterenol</td>
<td>1</td>
<td>28</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>5.57 [0.88, 35.27]</td>
</tr>
<tr>
<td>3 PEF @ 30 minutes (% predicted)</td>
<td>2</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3.1 Ipratropium bromide versus salbutamol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>3.2 Atropine sulphate versus metaproterenol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>4 PEF @ 120 minutes (% predicted)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>4.1 Ipratropium bromide versus salbutamol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>5 FEV1 @ 30 minutes (litres/sec)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>5.1 Ipratropium bromide versus fenoterol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>6 FEV1 @ 30 minutes (% predicted)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>6.1 Oxitropium bromide versus fenoterol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>7 FEV1 @ 120 minutes (litres/sec)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>7.1 Ipratropium bromide versus fenoterol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>8 Pulmonary index @ 30 mins</td>
<td>2</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>8.1 Ipratropium bromide versus fenoterol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>8.2 Atropine sulfate versus metaproterenol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>9 Pulmonary index @ 120 mins</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>9.1 Ipratropium bromide versus fenoterol</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>Outcome or subgroup title</td>
<td>No. of studies</td>
<td>No. of participants</td>
<td>Statistical method</td>
<td>Effect size</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>--------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>1 Treatment failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Ipratropium bromide</td>
<td>4</td>
<td>173</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>2.65 [1.20, 5.88]</td>
</tr>
<tr>
<td>versus ipratropium bromide</td>
<td>3</td>
<td>144</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>3.67 [1.41, 9.50]</td>
</tr>
<tr>
<td>plus beta2-agonist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 Atropine sulphate</td>
<td>1</td>
<td>29</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>1.02 [0.21, 4.98]</td>
</tr>
<tr>
<td>versus atropine sulphate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus metaproterenol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Admission to hospital</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Ipratropium bromide</td>
<td>3</td>
<td>141</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>5.90 [1.20, 29.05]</td>
</tr>
<tr>
<td>versus ipratropium bromide</td>
<td>2</td>
<td>112</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>5.69 [0.25, 128.50]</td>
</tr>
<tr>
<td>plus beta2-agonist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 Atropine sulfate</td>
<td>1</td>
<td>29</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>6.0 [0.95, 37.76]</td>
</tr>
<tr>
<td>versus atropine sulfate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus metaproterenol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Participants requiring no repeat nebulisation</td>
<td>1</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>3.1 Moderate-severe acute asthma</td>
<td>1</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
<td></td>
</tr>
<tr>
<td>4 PEF @ 30 minutes (% predicted)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.1 Ipratropium bromide</td>
<td>2</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>versus ipratropium bromide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus salbutamol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.2 Atropine sulphate</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>versus atropine sulphate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus metaproterenol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 PEF @ 120 minutes (% predicted)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.1 Ipratropium bromide</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>versus ipratropium bromide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus salbutamol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 FEV1 @ 30 minutes (litres/sec)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.1 Ipratropium versus</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>ipratropium bromide plus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>salbutamol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 FEV1 @ 120 mins (litres/sec)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.1 Ipratropium versus</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>ipratropium bromide plus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fenoterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Pulmonary index @ 30 mins</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1 Ipratropium bromide</td>
<td>2</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>versus ipratropium bromide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus fenoterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2 Atropine sulphate</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>versus atropine sulphate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus metaproterenol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Pulmonary index @ 120 mins</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1 Ipratropium versus</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>ipratropium bromide plus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fenoterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison I Anticholinergic agents versus short-acting beta2-agonist, Outcome I Treatment failure.

Review: Anticholinergic therapy for acute asthma in children

Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist

Outcome: 1 Treatment failure

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic n/N</th>
<th>Beta2 agonists n/N</th>
<th>Odds Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Odds Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Ipratropium bromide versus beta2-agonists</td>
<td>Calvo 1998 11/40</td>
<td>6/40</td>
<td>45.4 %</td>
<td>2.15 [ 0.71, 6.53 ]</td>
<td>45.4 %</td>
</tr>
<tr>
<td></td>
<td>Cook 1985 8/16</td>
<td>5/16</td>
<td>26.1 %</td>
<td>2.20 [ 0.52, 9.30 ]</td>
<td>26.1 %</td>
</tr>
<tr>
<td></td>
<td>Watson 1988 2/16</td>
<td>0/15</td>
<td>4.6 %</td>
<td>5.34 [ 0.24, 121.00 ]</td>
<td>4.6 %</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>72</td>
<td>71</td>
<td>76.1 %</td>
<td>2.36 [ 1.02, 5.47 ]</td>
<td>2.36 [ 1.02, 5.47 ]</td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td>21 (Anticholinergic), 11 (Beta2 agonists)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>Chi² = 0.30, df = 2 (P = 0.86); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>Z = 2.00 (P = 0.045)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Atropine sulphate versus metaproterenol</td>
<td>Guill 1987 9/13</td>
<td>8/15</td>
<td>23.9 %</td>
<td>1.97 [ 0.42, 9.32 ]</td>
<td>23.9 %</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>13</td>
<td>15</td>
<td>23.9 %</td>
<td>1.97 [ 0.42, 9.32 ]</td>
<td>1.97 [ 0.42, 9.32 ]</td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td>9 (Anticholinergic), 8 (Beta2 agonists)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>Z = 0.85 (P = 0.39)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>85</td>
<td>86</td>
<td>100.0 %</td>
<td>2.27 [ 1.08, 4.75 ]</td>
<td>2.27 [ 1.08, 4.75 ]</td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td>30 (Anticholinergic), 19 (Beta2 agonists)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>Chi² = 0.33, df = 3 (P = 0.95); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>Z = 2.17 (P = 0.030)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for subgroup differences:</strong></td>
<td>Chi² = 0.04, df = 1 (P = 0.84), I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 1.2. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 2 Admission to hospital.

**Review:** Anticholinergic therapy for acute asthma in children

**Comparison:** 1 Anticholinergic agents versus short-acting beta2-agonist

**Outcome:** 2 Admission to hospital

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic n/N</th>
<th>Beta2 agonists n/N</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
<th>Odds Ratio M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipratropium bromide versus beta2-agonist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calvo 1998</td>
<td>0/40</td>
<td>0/40</td>
<td>0.0 [ 0.0, 0.0 ]</td>
<td></td>
</tr>
<tr>
<td>Watson 1988</td>
<td>2/16</td>
<td>0/15</td>
<td>5.34 [ 0.24, 121.00 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>56</strong></td>
<td><strong>55</strong></td>
<td><strong>5.34 [ 0.24, 121.00 ]</strong></td>
<td></td>
</tr>
<tr>
<td>Total events: 2 (Anticholinergic), 0 (Beta2 agonists)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 0.0, df = 0 (P = 1.00); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 1.05 (P = 0.29)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atropine sulphate versus metaproterenol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gull 1987</td>
<td>6/13</td>
<td>2/15</td>
<td>5.57 [ 0.88, 35.27 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>13</strong></td>
<td><strong>15</strong></td>
<td><strong>5.57 [ 0.88, 35.27 ]</strong></td>
<td></td>
</tr>
<tr>
<td>Total events: 6 (Anticholinergic), 2 (Beta2 agonists)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 1.82 (P = 0.068)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>69</strong></td>
<td><strong>70</strong></td>
<td><strong>5.50 [ 1.11, 27.16 ]</strong></td>
<td></td>
</tr>
<tr>
<td>Total events: 8 (Anticholinergic), 2 (Beta2 agonists)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Chi² = 0.00, df = 1 (P = 0.98); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 2.09 (P = 0.036)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.98), I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Favours anticholinergic Favours beta2 agonist
### Analysis 1.3. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 3 PEF @ 30 minutes (% predicted).

**Review:** Anticholinergic therapy for acute asthma in children  
**Comparison:** 1 Anticholinergic agents versus short-acting beta2-agonist  
**Outcome:** 3 PEF @ 30 minutes (% predicted)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic</th>
<th>Beta2 agonist</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>1 Ipratropium bromide versus salbutamol</td>
<td>Calvo 1998</td>
<td>40</td>
<td>78.1 (7.3)</td>
<td>40</td>
</tr>
<tr>
<td>2 Atropine sulphate versus metaproterenol</td>
<td>Guili 1987</td>
<td>11</td>
<td>39 (22)</td>
<td>8</td>
</tr>
</tbody>
</table>

**Analysis 1.4. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 4 PEF @ 120 minutes (% predicted).**

**Review:** Anticholinergic therapy for acute asthma in children  
**Comparison:** 1 Anticholinergic agents versus short-acting beta2-agonist  
**Outcome:** 4 PEF @ 120 minutes (% predicted)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ipratropium bromide</th>
<th>Salbutamol</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>1 Ipratropium bromide versus salbutamol</td>
<td>Calvo 1998</td>
<td>40</td>
<td>95.6 (4.3)</td>
<td>40</td>
</tr>
</tbody>
</table>
Analysis 1.5. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 5 FEV1 @ 30 minutes (litres/sec).

Review: Anticholinergic therapy for acute asthma in children

Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist

Outcome: 5 FEV1 @ 30 minutes (litres/sec)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic</th>
<th>Fenoterol</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Ipratropium bromide versus fenoterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Watson 1988</td>
<td>16</td>
<td>1.51 (0.84)</td>
<td>15</td>
<td>1.86 (0.85)</td>
</tr>
</tbody>
</table>

Favours fenoterol  Favours anticholinergic

Analysis 1.6. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 6 FEV1 @ 30 minutes (% predicted).

Review: Anticholinergic therapy for acute asthma in children

Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist

Outcome: 6 FEV1 @ 30 minutes (% predicted)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic</th>
<th>Fenoterol</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Oxitropium bromide versus fenoterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Bever 1994</td>
<td>10</td>
<td>82.9 (9.6)</td>
<td>10</td>
<td>83 (10.1)</td>
</tr>
</tbody>
</table>

Favours fenoterol  Favours anticholinergic
**Analysis 1.7. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 7 FEV1 @120 minutes (litres/sec).**

Review: Anticholinergic therapy for acute asthma in children

Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist

Outcome: 7 FEV1 @120 minutes (litres/sec)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ipratropium bromide</th>
<th>Fenoterol</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>1 Ipratropium bromide versus fenoterol</td>
<td>16</td>
<td>1.48 (0.8)</td>
<td>15</td>
<td>1.89 (0.89)</td>
</tr>
</tbody>
</table>

Favours fenoterol

**Analysis 1.8. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 8 Pulmonary index @ 30 mins.**

Review: Anticholinergic therapy for acute asthma in children

Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist

Outcome: 8 Pulmonary index @ 30 mins

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic</th>
<th>Beta2 agonist</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>1 Ipratropium bromide versus fenoterol</td>
<td>16</td>
<td>4.56 (1.32)</td>
<td>15</td>
<td>3.87 (1.24)</td>
</tr>
<tr>
<td>2 Atropine sulfate versus metaproterenol</td>
<td>13</td>
<td>5.3 (3.3)</td>
<td>15</td>
<td>3.7 (1.7)</td>
</tr>
</tbody>
</table>

Favours anticholinergic

Favours beta2 agonist
Analysis 1.9. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 9 Pulmonary index @ 120 mins.

Review: Anticholinergic therapy for acute asthma in children

Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist

Outcome: 9 Pulmonary index @ 120 mins

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ipratropium bromide</th>
<th>Fenoterol</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipratropium bromide versus fenoterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Watson 1988</td>
<td>16</td>
<td>15</td>
<td>1.79 [ 0.67, 2.91 ]</td>
<td></td>
</tr>
</tbody>
</table>

Analysis 2.1. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 1 Treatment failure.

Review: Anticholinergic therapy for acute asthma in children

Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists

Outcome: 1 Treatment failure

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergics</th>
<th>Combination</th>
<th>Odds Ratio</th>
<th>Weight</th>
<th>Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipratropium bromide versus ipratropium bromide plus beta2-agonist</td>
<td>11/40</td>
<td>2/40</td>
<td>18.3 %</td>
<td>7.21 [ 1.48, 35.07 ]</td>
<td></td>
</tr>
<tr>
<td>Cook 1985</td>
<td>8/16</td>
<td>6/16</td>
<td>37.9 %</td>
<td>1.67 [ 0.41, 6.82 ]</td>
<td></td>
</tr>
<tr>
<td>Watson 1988</td>
<td>2/16</td>
<td>0/16</td>
<td>5.4 %</td>
<td>5.69 [ 0.25, 128.50 ]</td>
<td></td>
</tr>
</tbody>
</table>

Subtotal (95% CI) 72 72 61.6 % 3.67 [ 1.41, 9.50 ]

Total events: 21 (Anticholinergic), 8 (Combination)

Heterogeneity: Chi² = 1.98, df = 2 (P = 0.37); I² = 0.0%

Test for overall effect: Z = 2.67 (P = 0.0075)

2 Atropine sulphate versus atropine sulphate plus metaproterenol

Guil 1987 9/13 11/16 38.4 % 1.02 [ 0.21, 4.98 ]

Subtotal (95% CI) 13 16 38.4 % 1.02 [ 0.21, 4.98 ]

Total events: 9 (Anticholinergic), 11 (Combination)
### Analysis 2.2. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 2 Admission to hospital.

**Review:** Anticholinergic therapy for acute asthma in children

**Comparison:** 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists

**Outcome:** 2 Admission to hospital

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic</th>
<th>Combination</th>
<th>Odds Ratio</th>
<th>Weight</th>
<th>Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Ipratropium bromide versus ipratropium bromide plus beta2-agonist</td>
<td>0/40</td>
<td>0/40</td>
<td>0.00 [ 0.00, 0.00 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calvo 1998</td>
<td>0/40</td>
<td>0/40</td>
<td>0.00 [ 0.00, 0.00 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Watson 1988</td>
<td>2/16</td>
<td>0/16</td>
<td>5.69 [ 0.25, 128.50 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>56</strong></td>
<td><strong>56</strong></td>
<td><strong>5.69 [ 0.25, 128.50 ]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Atropine sulfate versus atropine sulfate plus metaproterenol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gull 1987</td>
<td>6/13</td>
<td>2/16</td>
<td>6.00 [ 0.95, 37.76 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>13</strong></td>
<td><strong>16</strong></td>
<td><strong>6.00 [ 0.95, 37.76 ]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Total (95% CI)</td>
<td><strong>69</strong></td>
<td><strong>72</strong></td>
<td><strong>5.90 [ 1.20, 29.05 ]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Heterogeneity:** not applicable

Test for overall effect: Z = 0.03 (P = 0.98).

Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.98), I² =0.0%
Analysis 2.3. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 3 Participants requiring no repeat nebulisation.

Review: Anticholinergic therapy for acute asthma in children

Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists

Outcome: 3 Participants requiring no repeat nebulisation

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ipratropium bromide</th>
<th>Combination</th>
<th>Odds Ratio</th>
<th>Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Moderate-severe acute asthma</td>
<td>8/15</td>
<td>10/15</td>
<td>0.57 [ 0.13, 2.50 ]</td>
<td></td>
</tr>
</tbody>
</table>

Favours combination Favours ipratropium

Analysis 2.4. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 4 PEF @ 30 minutes (% predicted).

Review: Anticholinergic therapy for acute asthma in children

Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists

Outcome: 4 PEF @ 30 minutes (% predicted)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic</th>
<th>Combination</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Mean(SD)</td>
<td>n</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>1 Ipratropium bromide versus ipratropium bromide plus salbutamol</td>
<td>40</td>
<td>78.1 (7.3)</td>
<td>40</td>
<td>85.1 (6.7)</td>
</tr>
<tr>
<td>2 Atropine sulphate versus atropine sulphate plus metaproterenol</td>
<td>11</td>
<td>39 (22)</td>
<td>10</td>
<td>48 (24)</td>
</tr>
</tbody>
</table>

Favours combination Favours anticholinergic
### Analysis 2.5. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 5 PEF @ 120 minutes (% predicted).

**Review:** Anticholinergic therapy for acute asthma in children  
**Comparison:** 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists  
**Outcome:** 5 PEF @ 120 minutes (% predicted)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic</th>
<th>Combination</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Ipratropium bromide versus ipratropium bromide plus salbutamol</td>
<td>Calvo 1998</td>
<td>40</td>
<td>95.6 (4.3)</td>
<td>40</td>
</tr>
</tbody>
</table>

Favours combination: Favours anticholinergic

### Analysis 2.6. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 6 FEV1 @ 30 minutes (litres/sec).

**Review:** Anticholinergic therapy for acute asthma in children  
**Comparison:** 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists  
**Outcome:** 6 FEV1 @ 30 minutes (litres/sec)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ipratropium bromide</th>
<th>Combination</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Ipratropium versus ipratropium bromide plus fenoterol</td>
<td>Watson 1988</td>
<td>16</td>
<td>1.51 (0.84)</td>
<td>16</td>
</tr>
</tbody>
</table>

Favours combination: Favours ipratropium
### Analysis 2.7. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 7 FEV1 @120 mins (litres/sec).

Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 7 FEV1 @120 mins (litres/sec)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ipratropium bromide</th>
<th>Combination</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N       Mean(SD)</td>
<td>N           Mean(SD)</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Ipratropium versus ipratropium bromide plus fenoterol Watson 1988</td>
<td>16 1.48 (0.8)</td>
<td>16 2.11 (1.05)</td>
<td>-0.63 [-1.28, 0.02]</td>
<td></td>
</tr>
</tbody>
</table>

Favours combination Favours ipratropium

### Analysis 2.8. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 8 Pulmonary index @ 30 mins.

Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 8 Pulmonary index @ 30 mins

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Anticholinergic</th>
<th>Combination</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N       Mean(SD)</td>
<td>N           Mean(SD)</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Ipratropium bromide versus ipratropium bromide plus fenoterol Watson 1988</td>
<td>16 4.56 (1.32)</td>
<td>16 3.53 (1.7)</td>
<td>1.03 [-0.02, 2.08]</td>
<td></td>
</tr>
<tr>
<td>2 Atropine sulfate versus atropine sulfate plus metaproterenol Gulli 1987</td>
<td>13 5.3 (3.3)</td>
<td>16 4 (2.4)</td>
<td>1.30 [-0.84, 3.44]</td>
<td></td>
</tr>
</tbody>
</table>

Favours anticholinergic Favours combination
Analysis 2.9. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists, Outcome 9 Pulmonary index @ 120 mins.

Review: Anticholinergic therapy for acute asthma in children

Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists

Outcome: 9 Pulmonary index @ 120 mins

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ipratropium bromide</th>
<th>Combination</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Ipratropium bromide versus ipratropium bromide plus fenoterol</td>
<td>16</td>
<td>4.72 (1.64)</td>
<td>16</td>
<td>2.56 (1.39)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Ipratropium bromide</th>
<th>Combination</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Ipratropium bromide versus ipratropium bromide plus fenoterol</td>
<td>16</td>
<td>4.72 (1.64)</td>
<td>16</td>
<td>2.56 (1.39)</td>
</tr>
</tbody>
</table>

ADDITIONAL TABLES

Table 1. Outcomes reported

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Calvo</th>
<th>Cook</th>
<th>Guill</th>
<th>Watson</th>
<th>Van Bever</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment failure</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Admission</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>PEF</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt;</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>FEF&lt;sub&gt;25...75&lt;/sub&gt;</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Residual bronchodilation (FEV&lt;sub&gt;1&lt;/sub&gt; and FEF&lt;sub&gt;25...75&lt;/sub&gt;)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>
Table 1. Outcomes reported  (Continued)

| Clinical scores | Yes (TAL score) | Yes (in-house 4-point scale. Wheeze, air entry on auscultation, respiratory distress measured) | Yes (Pulmonary Index - respiratory rate, wheezing score, I/E ratio, accessory muscle use) | Yes (Pulmonary Index - respiratory rate, wheezing score, I/E ratio, accessory muscle use) | No |
| Need for additional medication | Yes (need for bronchodilator/steroid and repeat nebulisation) | Yes (repeat nebulisation and need for IV therapy) | Yes (repeat nebulisation and need for IV therapy) | No | No |
| Withdrawals | No patients withdrew | 3 patients had treatment failure and dropped out | 10 episodes of wheezing had treatment failure | No patients withdrew; 2 children required hospital admission at the end of the study because of treatment failure | Not reported |
| Pulse oximetry | No | No | No | Yes | No |
| Side effects | Yes (no patient suffered SEs) | Yes (no patient suffered SEs) | Yes (no patient suffered SEs) | Yes (no patient suffered SEs) | Yes (no patient suffered SEs) |

ED: emergency department; FEF_{25−75}: forced expiratory flow at the 25 to the 75% point of forced vital capacity; FEV_{1}: forced expiratory volume in the first second; I/E ratio: inspiration/expiration ratio; IV: intravenous; PEF: peak expiratory flow; SE: side effects; TAL: a clinical scoring system based on several markers such as respiratory rate, wheezing and cyanosis (the scale runs from 0 to 12, where 12 indicates a very severe illness).

Table 2. TAL scores measured in Calvo 1998

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>0 minutes</th>
<th>15 minutes</th>
<th>30 minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipratropium (IP)</td>
<td>5.6 (SD 0.7)</td>
<td>5.4 (SD 0.7)</td>
<td>4.2 (SD 0.9)</td>
</tr>
<tr>
<td>Salbutamol (SAL)</td>
<td>5.6 (SD 0.7)</td>
<td>4.5 (SD 1.0)</td>
<td>3.3 (SD 1.1)</td>
</tr>
<tr>
<td>Combination (IP + SAL)</td>
<td>6.0 (SD 0.8)</td>
<td>4.3 (SD 1.2)</td>
<td>2.8 (SD 1.0)</td>
</tr>
<tr>
<td>P value IP versus SAL</td>
<td>&gt; 0.05</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>P value IP versus IP + SAL</td>
<td>&gt; 0.05</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)

Electronic searches: core databases

<table>
<thead>
<tr>
<th>Database</th>
<th>Frequency of search</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDLINE (Ovid)</td>
<td>Weekly</td>
</tr>
<tr>
<td>EMBASE (Ovid)</td>
<td>Weekly</td>
</tr>
<tr>
<td>CENTRAL (The Cochrane Library)</td>
<td>Quarterly</td>
</tr>
<tr>
<td>PsycINFO (Ovid)</td>
<td>Monthly</td>
</tr>
<tr>
<td>CINAHL (EBSCO)</td>
<td>Monthly</td>
</tr>
<tr>
<td>AMED (EBSCO)</td>
<td>Monthly</td>
</tr>
</tbody>
</table>

Handsearches: core respiratory conference abstracts

<table>
<thead>
<tr>
<th>Conference</th>
<th>Years searched</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Academy of Allergy, Asthma and Immunology (AAAAI)</td>
<td>2001 onwards</td>
</tr>
<tr>
<td>American Thoracic Society (ATS)</td>
<td>2001 onwards</td>
</tr>
<tr>
<td>Asia Pacific Society of Respirology (APSR)</td>
<td>2004 onwards</td>
</tr>
<tr>
<td>British Thoracic Society Winter Meeting (BTS)</td>
<td>2000 onwards</td>
</tr>
<tr>
<td>Chest Meeting</td>
<td>2003 onwards</td>
</tr>
<tr>
<td>International Primary Care Respiratory Group Congress (IPCRG)</td>
<td>2002 onwards</td>
</tr>
<tr>
<td>Thoracic Society of Australia and New Zealand (TSANZ)</td>
<td>1999 onwards</td>
</tr>
</tbody>
</table>

MEDLINE search strategy used to identify trials for the CAGR

Anticholinergic therapy for acute asthma in children (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency$)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15

Filter to identify RCTs
1. exp "clinical trial [publication type]"/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases

Appendix 2. CENTRAL search strategy
#1 MeSH descriptor Asthma explode all trees
#2 (asthma*)
#3 (wheez*)
#4 MeSH descriptor Respiratory Sounds, this term only
#5 MeSH descriptor Bronchial Spasm, this term only
#6 (bronchospas*)
#7 (bronch* near/3 spasm*)
#8 (bronchoconstrict*)
#9 MeSH descriptor Bronchoconstriction, this term only
#10 (bronch* near/3 constrict*)
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 MeSH descriptor Cholinergic Antagonists explode all trees
#13 anticholinergic* or anti-cholinergic* or cholinergic* or muscarinic* or antimuscarinic or ipratropium or tiotropium or atropine or atrovent or oxtropium or Sch1000 or duovent
#14 (#12 OR #13)
#15 (#11 AND #14)
#16 MeSH descriptor Child explode all trees
#17 MeSH descriptor Infant explode all trees
#18 MeSH descriptor Adolescent explode all trees
#19 MeSH descriptor Pediatrics explode all trees
#20 child* or paediat* or pediat* or toddler* or bab* or young* or preschool* or "pre school*" or pre-school* or newborn* or "newborn*" or new-born* or neo-nat* or neonat*
#21 (#16 OR #17 OR #18 OR #19 OR #20)
#22 (#15 AND #21)

**HISTORY**

Protocol first published: Issue 2, 2002
Review first published: Issue 4, 2012

**CONTRIBUTIONS OF AUTHORS**

The original protocol was written by Satish Bangalore, Anna Bara and Nicola McDonald. The protocol was revised prior to commencing the review by Laurel Teoh (LT) and Anne Chang (AC).

LT and AC wrote the review and independently selected, reviewed, and extracted the data from the papers. All authors reviewed the submitted review.

**DECLARATIONS OF INTEREST**

None known.

**SOURCES OF SUPPORT**

**Internal sources**
- No sources of support supplied

**External sources**
- Australian Cochrane Airway Scholarship, Australia.
  Support to LT
- National Health and Medical Research Council (NHMRC), Australia.
  Fellowship for AC (grant number 545216)
**DIFFERENCES BETWEEN PROTOCOL AND REVIEW**

We subgrouped the data by anticholinergic type. We added withdrawals and requirement for additional medication as secondary outcomes and pooled the data. We removed parent and patient perceptions and physician assessment as outcomes as they are not clearly defined outcomes.

**NOTES**

None relevant.